ID   CCN6_HUMAN              Reviewed;         354 AA.
AC   O95389; Q3KR29; Q5H8W4; Q6UXH6;
DT   15-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-1999, sequence version 1.
DT   07-APR-2021, entry version 164.
DE   RecName: Full=Cellular communication network factor 6;
DE   AltName: Full=CCN family member 6;
DE   AltName: Full=WNT1-inducible-signaling pathway protein 3 {ECO:0000303|PubMed:9843955};
DE            Short=WISP-3 {ECO:0000303|PubMed:9843955};
DE   Flags: Precursor;
GN   Name=CCN6 {ECO:0000312|HGNC:HGNC:12771};
GN   Synonyms=WISP3 {ECO:0000312|HGNC:HGNC:12771};
GN   ORFNames=UNQ462/PRO790/PRO956;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Bone marrow, and Fetal kidney;
RX   PubMed=9843955; DOI=10.1073/pnas.95.25.14717;
RA   Pennica D., Swanson T.A., Welsh J.W., Roy M.A., Lawrence D.A., Lee J.,
RA   Brush J., Taneyhill L.A., Deuel B., Lew M., Watanabe C., Cohen R.L.,
RA   Melham M.F., Finley G.G., Quirke P., Goddard A.D., Hillan K.J.,
RA   Gurney A.L., Botstein D., Levine A.J.;
RT   "WISP genes are members of the connective tissue growth factor family that
RT   are up-regulated in wnt-1-transformed cells and aberrantly expressed in
RT   human colon tumors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:14717-14722(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S., Huang A.,
RA   Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J., Lewis L., Liao D.,
RA   Mark M.R., Robbie E., Sanchez C., Schoenfeld J., Seshagiri S., Simmons L.,
RA   Singh J., Smith V., Stinson J., Vagts A., Vandlen R.L., Watanabe C.,
RA   Wieand D., Woods K., Xie M.-H., Yansura D.G., Yi S., Yu G., Yuan J.,
RA   Zhang M., Zhang Z., Goddard A.D., Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale effort to
RT   identify novel human secreted and transmembrane proteins: a bioinformatics
RT   assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=14574404; DOI=10.1038/nature02055;
RA   Mungall A.J., Palmer S.A., Sims S.K., Edwards C.A., Ashurst J.L.,
RA   Wilming L., Jones M.C., Horton R., Hunt S.E., Scott C.E., Gilbert J.G.R.,
RA   Clamp M.E., Bethel G., Milne S., Ainscough R., Almeida J.P., Ambrose K.D.,
RA   Andrews T.D., Ashwell R.I.S., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Barker D.J., Barlow K.F., Bates K., Beare D.M., Beasley H.,
RA   Beasley O., Bird C.P., Blakey S.E., Bray-Allen S., Brook J., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Carder C., Carter N.P.,
RA   Chapman J.C., Clark S.Y., Clark G., Clee C.M., Clegg S., Cobley V.,
RA   Collier R.E., Collins J.E., Colman L.K., Corby N.R., Coville G.J.,
RA   Culley K.M., Dhami P., Davies J., Dunn M., Earthrowl M.E., Ellington A.E.,
RA   Evans K.A., Faulkner L., Francis M.D., Frankish A., Frankland J.,
RA   French L., Garner P., Garnett J., Ghori M.J., Gilby L.M., Gillson C.J.,
RA   Glithero R.J., Grafham D.V., Grant M., Gribble S., Griffiths C.,
RA   Griffiths M.N.D., Hall R., Halls K.S., Hammond S., Harley J.L., Hart E.A.,
RA   Heath P.D., Heathcott R., Holmes S.J., Howden P.J., Howe K.L., Howell G.R.,
RA   Huckle E., Humphray S.J., Humphries M.D., Hunt A.R., Johnson C.M.,
RA   Joy A.A., Kay M., Keenan S.J., Kimberley A.M., King A., Laird G.K.,
RA   Langford C., Lawlor S., Leongamornlert D.A., Leversha M., Lloyd C.R.,
RA   Lloyd D.M., Loveland J.E., Lovell J., Martin S., Mashreghi-Mohammadi M.,
RA   Maslen G.L., Matthews L., McCann O.T., McLaren S.J., McLay K., McMurray A.,
RA   Moore M.J.F., Mullikin J.C., Niblett D., Nickerson T., Novik K.L.,
RA   Oliver K., Overton-Larty E.K., Parker A., Patel R., Pearce A.V., Peck A.I.,
RA   Phillimore B.J.C.T., Phillips S., Plumb R.W., Porter K.M., Ramsey Y.,
RA   Ranby S.A., Rice C.M., Ross M.T., Searle S.M., Sehra H.K., Sheridan E.,
RA   Skuce C.D., Smith S., Smith M., Spraggon L., Squares S.L., Steward C.A.,
RA   Sycamore N., Tamlyn-Hall G., Tester J., Theaker A.J., Thomas D.W.,
RA   Thorpe A., Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M.,
RA   West A.P., White S.S., Whitehead S.L., Whittaker H., Wild A., Willey D.J.,
RA   Wilmer T.E., Wood J.M., Wray P.W., Wyatt J.C., Young L., Younger R.M.,
RA   Bentley D.R., Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Dunham I.,
RA   Rogers J., Beck S.;
RT   "The DNA sequence and analysis of human chromosome 6.";
RL   Nature 425:805-811(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   SUBCELLULAR LOCATION, AND FUNCTION.
RX   PubMed=27252383; DOI=10.1242/jcs.186247;
RA   Patra M., Mahata S.K., Padhan D.K., Sen M.;
RT   "CCN6 regulates mitochondrial function.";
RL   J. Cell Sci. 129:2841-2851(2016).
RN   [7]
RP   INVOLVEMENT IN PPAC, VARIANTS PPAC ARG-78 AND TYR-145, VARIANT HIS-56,
RP   TISSUE SPECIFICITY, AND FUNCTION.
RX   PubMed=10471507; DOI=10.1038/12699;
RA   Hurvitz J.R., Suwairi W.M., Van Hul W., El-Shanti H., Superti-Furga A.,
RA   Roudier J., Holderbaum D., Pauli R.M., Herd J.K., Van Hul E.V.,
RA   Rezai-Delui H., Legius E., Le Merrer M., Al-Alami J., Bahabri S.A.,
RA   Warman M.L.;
RT   "Mutations in the CCN gene family member WISP3 cause progressive
RT   pseudorheumatoid dysplasia.";
RL   Nat. Genet. 23:94-98(1999).
RN   [8]
RP   VARIANTS PPAC 52-CYS--LEU-354 DEL AND ARG-78, AND VARIANTS HIS-56 AND
RP   GLU-83.
RX   PubMed=16152649; DOI=10.1002/ajmg.a.30906;
RA   Delague V., Chouery E., Corbani S., Ghanem I., Aamar S., Fischer J.,
RA   Levy-Lahad E., Urtizberea J.A., Megarbane A.;
RT   "Molecular study of WISP3 in nine families originating from the Middle-East
RT   and presenting with progressive pseudorheumatoid dysplasia: identification
RT   of two novel mutations, and description of a founder effect.";
RL   Am. J. Med. Genet. A 138A:118-126(2005).
RN   [9]
RP   VARIANTS PPAC 46-GLN--LEU-354 DEL AND TYR-114.
RX   PubMed=19064006; DOI=10.1016/j.bone.2008.11.005;
RA   Yue H., Zhang Z.L., He J.W.;
RT   "Identification of novel mutations in WISP3 gene in two unrelated Chinese
RT   families with progressive pseudorheumatoid dysplasia.";
RL   Bone 44:547-554(2009).
RN   [10]
RP   VARIANTS PPAC 52-CYS--LEU-354 DEL; TYR-78; ARG-114; 116-TYR--LEU-354 DEL;
RP   ARG-145; PRO-228; GLY-268 AND TYR-337, AND VARIANT GLU-83.
RX   PubMed=22987568; DOI=10.1002/ajmg.a.35620;
RA   Dalal A., Bhavani G.S., Togarrati P.P., Bierhals T., Nandineni M.R.,
RA   Danda S., Danda D., Shah H., Vijayan S., Gowrishankar K., Phadke S.R.,
RA   Bidchol A.M., Rao A.P., Nampoothiri S., Kutsche K., Girisha K.M.;
RT   "Analysis of the WISP3 gene in Indian families with progressive
RT   pseudorheumatoid dysplasia.";
RL   Am. J. Med. Genet. A 158A:2820-2828(2012).
RN   [11]
RP   VARIANTS PPAC TRP-114 AND PRO-334.
RX   PubMed=22685593; DOI=10.1371/journal.pone.0038643;
RA   Sun J., Xia W., He S., Zhao Z., Nie M., Li M., Jiang Y., Xing X., Wang O.,
RA   Meng X., Zhou X.;
RT   "Novel and recurrent mutations of WISP3 in two Chinese families with
RT   progressive pseudorheumatoid dysplasia.";
RL   PLoS ONE 7:E38643-E38643(2012).
RN   [12]
RP   VARIANTS PPAC 52-CYS--LEU-354 DEL; TYR-78; PHE-99; SER-100;
RP   116-TYR--LEU-354 DEL; ARG-145; 177-SER--LEU-354 DEL; VAL-226 AND TYR-337.
RX   PubMed=25988854; DOI=10.1002/ajmg.a.37164;
RA   Bhavani G.S., Shah H., Dalal A.B., Shukla A., Danda S., Aggarwal S.,
RA   Phadke S.R., Gupta N., Kabra M., Gowrishankar K., Gupta A., Bhat M.,
RA   Puri R.D., Bijarnia-Mahay S., Nampoothiri S., Mohanasundaram K.M.,
RA   Rajeswari S., Kulkarni A.M., Kulkarni M.L., Ranganath P., Ramadevi A.R.,
RA   Hariharan S.V., Girisha K.M.;
RT   "Novel and recurrent mutations in WISP3 and an atypical phenotype.";
RL   Am. J. Med. Genet. A 167A:2481-2484(2015).
RN   [13]
RP   VARIANTS PPAC GLY-223 AND 252-CYS--LEU-354 DEL.
RX   PubMed=25794430; DOI=10.1016/j.gene.2015.03.029;
RA   Luo H., Shi C., Mao C., Jiang C., Bao D., Guo J., Du P., Wang Y., Liu Y.,
RA   Liu X., Song B., Xu Y.;
RT   "A novel compound WISP3 mutation in a Chinese family with progressive
RT   pseudorheumatoid dysplasia.";
RL   Gene 564:35-38(2015).
RN   [14]
RP   VARIANTS PPAC 46-GLN--LEU-354 DEL; TRP-114; GLY-223 AND 286-SER--LEU-354
RP   DEL.
RX   PubMed=25738435; DOI=10.3892/mmr.2015.3430;
RA   Yu Y., Hu M., Xing X., Li F., Song Y., Luo Y., Ma H.;
RT   "Identification of a mutation in the WISP3 gene in three unrelated families
RT   with progressive pseudorheumatoid dysplasia.";
RL   Mol. Med. Report. 12:419-425(2015).
RN   [15]
RP   VARIANTS PPAC 52-CYS--LEU-354 DEL; TYR-78; 116-TYR--LEU-354 DEL; VAL-226
RP   AND TYR-337.
RX   PubMed=27436824; DOI=10.1302/2046-3758.57.2000520;
RA   Madhuri V., Santhanam M., Rajagopal K., Sugumar L.K., Balaji V.;
RT   "WISP3 mutational analysis in Indian patients diagnosed with progressive
RT   pseudorheumatoid dysplasia and report of a novel mutation at p.Y198.";
RL   Bone Joint Res. 5:301-306(2016).
RN   [16]
RP   VARIANT PPAC 52-CYS--LEU-354 DEL.
RX   PubMed=29092958; DOI=10.1101/mcs.a001990;
RA   Sailani M.R., Chappell J., Jingga I., Narasimha A., Zia A., Lynch J.L.,
RA   Mazrouei S., Bernstein J.A., Aryani O., Snyder M.P.;
RT   "WISP3 mutation associated with pseudorheumatoid dysplasia.";
RL   Cold Spring Harb. Mol. Case Stud. 4:0-0(2018).
CC   -!- FUNCTION: Plays a role in mitochondrial electron transport and
CC       mitochondrial respiration (PubMed:27252383). Through its regulation of
CC       the mitochondrial function may play a role in normal postnatal skeletal
CC       growth and cartilage homeostasis (PubMed:27252383, PubMed:10471507).
CC       {ECO:0000269|PubMed:10471507, ECO:0000269|PubMed:27252383}.
CC   -!- SUBCELLULAR LOCATION: Secreted {ECO:0000269|PubMed:27252383}.
CC       Mitochondrion {ECO:0000269|PubMed:27252383}. Note=Associated with
CC       membranes. {ECO:0000269|PubMed:27252383}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O95389-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O95389-2; Sequence=VSP_037803;
CC   -!- TISSUE SPECIFICITY: Predominant expression in adult kidney and testis
CC       and fetal kidney. Weaker expression found in placenta, ovary, prostate
CC       and small intestine (PubMed:9843955, PubMed:10471507). Also expressed
CC       in skeletally-derived cells such as synoviocytes and articular
CC       cartilage chondrocytes (PubMed:10471507). {ECO:0000269|PubMed:10471507,
CC       ECO:0000269|PubMed:9843955}.
CC   -!- DISEASE: Progressive pseudorheumatoid arthropathy of childhood (PPAC)
CC       [MIM:208230]: Autosomal recessive disorder characterized by stiffness
CC       and swelling of joints, motor weakness and joint contractures. Signs
CC       and symptoms of the disease develop typically between three and eight
CC       years of age. This progressive disease is a primary disorder of
CC       articular cartilage with continued cartilage loss and destructive bone
CC       changes with aging. {ECO:0000269|PubMed:10471507,
CC       ECO:0000269|PubMed:16152649, ECO:0000269|PubMed:19064006,
CC       ECO:0000269|PubMed:22685593, ECO:0000269|PubMed:22987568,
CC       ECO:0000269|PubMed:25738435, ECO:0000269|PubMed:25794430,
CC       ECO:0000269|PubMed:25988854, ECO:0000269|PubMed:27436824,
CC       ECO:0000269|PubMed:29092958}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the CCN family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/WISP3ID469ch6q22.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF100781; AAC96323.1; -; mRNA.
DR   EMBL; AY358349; AAQ88715.1; -; mRNA.
DR   EMBL; AY358350; AAQ88716.1; -; mRNA.
DR   EMBL; Z99289; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL512299; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471051; EAW48273.1; -; Genomic_DNA.
DR   EMBL; CH471051; EAW48275.1; -; Genomic_DNA.
DR   EMBL; BC105941; AAI05942.1; -; mRNA.
DR   CCDS; CCDS5097.1; -. [O95389-1]
DR   CCDS; CCDS5098.1; -. [O95389-1]
DR   RefSeq; NP_003871.1; NM_003880.3. [O95389-1]
DR   RefSeq; NP_937882.1; NM_198239.1. [O95389-1]
DR   RefSeq; XP_011534522.1; XM_011536220.1. [O95389-1]
DR   SMR; O95389; -.
DR   BioGRID; 114365; 7.
DR   IntAct; O95389; 4.
DR   STRING; 9606.ENSP00000357655; -.
DR   GlyGen; O95389; 2 sites.
DR   iPTMnet; O95389; -.
DR   PhosphoSitePlus; O95389; -.
DR   BioMuta; WISP3; -.
DR   PaxDb; O95389; -.
DR   PeptideAtlas; O95389; -.
DR   PRIDE; O95389; -.
DR   ProteomicsDB; 50840; -. [O95389-1]
DR   ProteomicsDB; 50841; -. [O95389-2]
DR   Antibodypedia; 32438; 182 antibodies.
DR   Ensembl; ENST00000230529; ENSP00000230529; ENSG00000112761. [O95389-1]
DR   Ensembl; ENST00000368666; ENSP00000357655; ENSG00000112761. [O95389-1]
DR   Ensembl; ENST00000604763; ENSP00000473777; ENSG00000112761. [O95389-1]
DR   GeneID; 8838; -.
DR   KEGG; hsa:8838; -.
DR   UCSC; uc003pvm.4; human. [O95389-1]
DR   CTD; 8838; -.
DR   DisGeNET; 8838; -.
DR   GeneCards; CCN6; -.
DR   GeneReviews; CCN6; -.
DR   HGNC; HGNC:12771; CCN6.
DR   HPA; ENSG00000112761; Tissue enhanced (epididymis).
DR   MalaCards; CCN6; -.
DR   MIM; 208230; phenotype.
DR   MIM; 603400; gene.
DR   neXtProt; NX_O95389; -.
DR   OpenTargets; ENSG00000112761; -.
DR   Orphanet; 1159; Progressive pseudorheumatoid arthropathy of childhood.
DR   PharmGKB; PA37374; -.
DR   VEuPathDB; HostDB:ENSG00000112761.18; -.
DR   eggNOG; ENOG502QW30; Eukaryota.
DR   GeneTree; ENSGT00940000160119; -.
DR   HOGENOM; CLU_063247_2_0_1; -.
DR   InParanoid; O95389; -.
DR   OMA; CACKSVG; -.
DR   OrthoDB; 601212at2759; -.
DR   PhylomeDB; O95389; -.
DR   TreeFam; TF326070; -.
DR   PathwayCommons; O95389; -.
DR   BioGRID-ORCS; 8838; 3 hits in 986 CRISPR screens.
DR   GeneWiki; WNT1-inducible-signaling_pathway_protein_3; -.
DR   GenomeRNAi; 8838; -.
DR   Pharos; O95389; Tbio.
DR   PRO; PR:O95389; -.
DR   Proteomes; UP000005640; Chromosome 6.
DR   RNAct; O95389; protein.
DR   Bgee; ENSG00000112761; Expressed in tibia and 109 other tissues.
DR   ExpressionAtlas; O95389; baseline and differential.
DR   Genevisible; O95389; HS.
DR   GO; GO:0031012; C:extracellular matrix; IBA:GO_Central.
DR   GO; GO:0005615; C:extracellular space; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProtKB.
DR   GO; GO:0008083; F:growth factor activity; IEA:UniProtKB-KW.
DR   GO; GO:0008201; F:heparin binding; IBA:GO_Central.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IEA:InterPro.
DR   GO; GO:0005178; F:integrin binding; IBA:GO_Central.
DR   GO; GO:0007155; P:cell adhesion; IBA:GO_Central.
DR   GO; GO:0007267; P:cell-cell signaling; TAS:ProtInc.
DR   GO; GO:0016525; P:negative regulation of angiogenesis; IDA:MGI.
DR   GO; GO:0060548; P:negative regulation of cell death; IBA:GO_Central.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IDA:MGI.
DR   GO; GO:0051881; P:regulation of mitochondrial membrane potential; IMP:UniProtKB.
DR   GO; GO:1903426; P:regulation of reactive oxygen species biosynthetic process; IMP:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; IBA:GO_Central.
DR   Gene3D; 2.20.100.10; -; 1.
DR   InterPro; IPR006207; Cys_knot_C.
DR   InterPro; IPR006208; Glyco_hormone_CN.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR000867; IGFBP-like.
DR   InterPro; IPR012395; IGFBP_CNN.
DR   InterPro; IPR017891; Insulin_GF-bd_Cys-rich_CS.
DR   InterPro; IPR043973; TSP1_CCN.
DR   InterPro; IPR000884; TSP1_rpt.
DR   InterPro; IPR036383; TSP1_rpt_sf.
DR   Pfam; PF00007; Cys_knot; 1.
DR   Pfam; PF00219; IGFBP; 1.
DR   Pfam; PF19035; TSP1_CCN; 1.
DR   PIRSF; PIRSF036495; IGFBP_rP_CNN; 1.
DR   SMART; SM00041; CT; 1.
DR   SMART; SM00121; IB; 1.
DR   SMART; SM00209; TSP1; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   SUPFAM; SSF82895; SSF82895; 1.
DR   PROSITE; PS01225; CTCK_2; 1.
DR   PROSITE; PS00222; IGFBP_N_1; 1.
DR   PROSITE; PS51323; IGFBP_N_2; 1.
DR   PROSITE; PS50092; TSP1; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Disease variant; Disulfide bond; Glycoprotein;
KW   Growth factor; Mitochondrion; Reference proteome; Secreted; Signal.
FT   SIGNAL          1..23
FT                   /evidence="ECO:0000255"
FT   CHAIN           24..354
FT                   /note="Cellular communication network factor 6"
FT                   /id="PRO_0000014412"
FT   DOMAIN          44..117
FT                   /note="IGFBP N-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00653"
FT   DOMAIN          208..253
FT                   /note="TSP type-1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00210"
FT   DOMAIN          268..342
FT                   /note="CTCK"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00039"
FT   CARBOHYD        178
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        308
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        268..305
FT                   /evidence="ECO:0000250"
FT   DISULFID        285..319
FT                   /evidence="ECO:0000250"
FT   DISULFID        296..335
FT                   /evidence="ECO:0000250"
FT   DISULFID        299..337
FT                   /evidence="ECO:0000250"
FT   DISULFID        304..341
FT                   /evidence="ECO:0000250"
FT   VAR_SEQ         1
FT                   /note="M -> MNKRRLLYPSGWLHGPSDM (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:12975309,
FT                   ECO:0000303|PubMed:15489334"
FT                   /id="VSP_037803"
FT   VARIANT         46..354
FT                   /note="Missing (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:19064006,
FT                   ECO:0000269|PubMed:25738435"
FT                   /id="VAR_081483"
FT   VARIANT         52..354
FT                   /note="Missing (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:16152649,
FT                   ECO:0000269|PubMed:22987568, ECO:0000269|PubMed:25988854,
FT                   ECO:0000269|PubMed:27436824, ECO:0000269|PubMed:29092958"
FT                   /id="VAR_081484"
FT   VARIANT         56
FT                   /note="Q -> H (in dbSNP:rs1230345)"
FT                   /evidence="ECO:0000269|PubMed:10471507,
FT                   ECO:0000269|PubMed:16152649"
FT                   /id="VAR_016224"
FT   VARIANT         60
FT                   /note="R -> C (in dbSNP:rs17073260)"
FT                   /id="VAR_049567"
FT   VARIANT         78
FT                   /note="C -> R (in PPAC; dbSNP:rs121908902)"
FT                   /evidence="ECO:0000269|PubMed:10471507,
FT                   ECO:0000269|PubMed:16152649"
FT                   /id="VAR_016225"
FT   VARIANT         78
FT                   /note="C -> Y (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:22987568,
FT                   ECO:0000269|PubMed:25988854, ECO:0000269|PubMed:27436824"
FT                   /id="VAR_081485"
FT   VARIANT         83
FT                   /note="G -> E (in dbSNP:rs147337485)"
FT                   /evidence="ECO:0000269|PubMed:16152649,
FT                   ECO:0000269|PubMed:22987568"
FT                   /id="VAR_081486"
FT   VARIANT         99
FT                   /note="Y -> F (in PPAC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:25988854"
FT                   /id="VAR_081652"
FT   VARIANT         100
FT                   /note="C -> S (in PPAC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:25988854"
FT                   /id="VAR_081653"
FT   VARIANT         114
FT                   /note="C -> R (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:22987568"
FT                   /id="VAR_081487"
FT   VARIANT         114
FT                   /note="C -> W (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:22685593,
FT                   ECO:0000269|PubMed:25738435"
FT                   /id="VAR_081488"
FT   VARIANT         114
FT                   /note="C -> Y (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:19064006"
FT                   /id="VAR_081654"
FT   VARIANT         116..354
FT                   /note="Missing (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:22987568,
FT                   ECO:0000269|PubMed:25988854, ECO:0000269|PubMed:27436824"
FT                   /id="VAR_081489"
FT   VARIANT         145
FT                   /note="C -> R (in PPAC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22987568,
FT                   ECO:0000269|PubMed:25988854"
FT                   /id="VAR_081490"
FT   VARIANT         145
FT                   /note="C -> Y (in PPAC; unknown pathological significance;
FT                   dbSNP:rs121908899)"
FT                   /evidence="ECO:0000269|PubMed:10471507"
FT                   /id="VAR_081655"
FT   VARIANT         177..354
FT                   /note="Missing (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:25988854"
FT                   /id="VAR_081656"
FT   VARIANT         223
FT                   /note="C -> G (in PPAC; dbSNP:rs782813346)"
FT                   /evidence="ECO:0000269|PubMed:25738435,
FT                   ECO:0000269|PubMed:25794430"
FT                   /id="VAR_081491"
FT   VARIANT         226
FT                   /note="G -> V (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:25988854,
FT                   ECO:0000269|PubMed:27436824"
FT                   /id="VAR_081657"
FT   VARIANT         228
FT                   /note="S -> P (in PPAC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22987568"
FT                   /id="VAR_081492"
FT   VARIANT         252..354
FT                   /note="Missing (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:25794430"
FT                   /id="VAR_081658"
FT   VARIANT         268
FT                   /note="C -> G (in PPAC; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:22987568"
FT                   /id="VAR_081493"
FT   VARIANT         286..354
FT                   /note="Missing (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:25738435"
FT                   /id="VAR_081494"
FT   VARIANT         334
FT                   /note="S -> P (in PPAC; dbSNP:rs121908903)"
FT                   /evidence="ECO:0000269|PubMed:22685593"
FT                   /id="VAR_081659"
FT   VARIANT         337
FT                   /note="C -> Y (in PPAC)"
FT                   /evidence="ECO:0000269|PubMed:22987568,
FT                   ECO:0000269|PubMed:25988854, ECO:0000269|PubMed:27436824"
FT                   /id="VAR_081495"
FT   CONFLICT        200
FT                   /note="N -> D (in Ref. 2; AAQ88715)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   354 AA;  39293 MW;  67F48D0D5C2F5EE3 CRC64;
     MQGLLFSTLL LAGLAQFCCR VQGTGPLDTT PEGRPGEVSD APQRKQFCHW PCKCPQQKPR
     CPPGVSLVRD GCGCCKICAK QPGEICNEAD LCDPHKGLYC DYSVDRPRYE TGVCAYLVAV
     GCEFNQVHYH NGQVFQPNPL FSCLCVSGAI GCTPLFIPKL AGSHCSGAKG GKKSDQSNCS
     LEPLLQQLST SYKTMPAYRN LPLIWKKKCL VQATKWTPCS RTCGMGISNR VTNENSNCEM
     RKEKRLCYIQ PCDSNILKTI KIPKGKTCQP TFQLSKAEKF VFSGCSSTQS YKPTFCGICL
     DKRCCIPNKS KMITIQFDCP NEGSFKWKML WITSCVCQRN CREPGDIFSE LKIL
//
